Alkem Laboratories Merger & Restructuring
Alkem Laboratories held an NCLT-convened meeting of equity shareholders to approve the Scheme of Amalgamation with Adroit Biomed Limited. The scheme received majority shareholder approval.
ALFA Filings
Every announcement, straight from the exchange
Every Alkem Laboratories merger & restructuring announcement on NSE and BSE, newest first, each with its own page.
Time
4 announcements with these filters
Alkem Laboratories held an NCLT-convened meeting of equity shareholders to approve the Scheme of Amalgamation with Adroit Biomed Limited. The scheme received majority shareholder approval.
Alkem Laboratories completed the acquisition of a 51-55% stake in Swiss firm Occlutech Holding AG. Occlutech now becomes a step-down subsidiary of the company.
Alkem Laboratories acquired equity shares worth Rs. 1,100 Crore in its subsidiary, Alkem Medtech, via a rights issue. The investment supports Medtech's cardiovascular and orthopedic business.
Alkem Medtech will acquire 51-55% of Occlutech Holding AG through a supplementary Share Purchase Agreement. This acquisition expands Alkem's international footprint.